Professor Christopher Goldring BSc, PhD

Research Grants

Translational Safety Biomarker Pipeline: Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease (TransBioLine)

EUROPEAN COMMISSION

February 2019 - January 2025

Development of a multicell model of human liver

WANNAN MEDICAL COLLEGE (CHINA)🚩

January 2017 - December 2017

Biomarker analysis from BACE inhibitor project

JANSSEN PHARMACEUTICALS (BELGIUM)

November 2017 - March 2018

TransQST: Translational quantitative systems toxicology to improve the understanding of the safety of medicines

EUROPEAN COMMISSION

January 2017 - August 2022

To examine the potential preclinical value of mechanism-based biomarkers of DILI over more established and widely accepted clinical diagnostics related to liver histopathology. Development and qualification of the use of a combination of established and mechanism-based biomarkers (HMGB1(+Ac/-Ac); cytokeratin 18 or ccK18; Mir122) for DILI assay in preclinical studies (CDSS DILI Project)

MERCK & CO., INC. (USA)

February 2020 - February 2024

Identification of actionable drug targets in extra-hepatic Cholangiocarcinoma

AMMF THE CHOLANGIOCARCINOMA CHARITY(THE ALAN MOREMENT MEMORIAL FUND)(UK)

December 2017 - December 2018

Evaluation of Organoids and Systems Biology to develop Adverse Outcome Pathways of Gastrointestinal Toxicity (ITTP Studentship)

MEDICAL RESEARCH COUNCIL

October 2018 - September 2022

Determining the efficacy and safety of cancer chemotherapeutics for cholangiocarcinoma (CCA) using Human Precision Cut Tissue Slices (hPCTS).

NATIONAL CENTRE FOR THE REP, REF AND RED OF ANIMALS USED IN RESEARCH (NC3RS)

August 2021 - September 2023

Senior Technician at ULIV for TransBioLine

ELI LILLY AND COMPANY LTD (UK)

April 2022 - March 2024

Automated high-resolution microscope platform with robotics to study pharmacodynamics in 3D cell cultures

MEDICAL RESEARCH COUNCIL

November 2022 - March 2023

Bench Fees for Mohammed N. Bosakhar (201284267)

THE CULTURAL OFFICE OF THE EMBASSY OF THE STATE OF KUWAIT (UK)

January 2022 - January 2025

Senior Technician at ULIV for TransBioLine

PFIZER LTD (UK)

April 2022 - March 2024

Senior Technician at ULIV for TransBioLine

MERCK SHARP & DOHME LTD (UK)

April 2022 - March 2024

Preclinical evaluation of Nrf2 inhibition as a means to improve chemotherapeutic efficacy in patients with pancreatic cancer

PANCREATIC CANCER RESEARCH FUND (UK)

February 2016 - January 2020

Mechanistic investigation and risk:benefit analysis of the use of brusatol as a novel adjuvant for overcoming cisplatin resistance in bladder cancer

NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH (UK)

February 2016 - February 2018

Nanoparticle Interventions for Colorectal Cancer

CANCER RESEARCH UK (UK)

October 2016 - September 2021

Developing a collaborative resource for ChIP based analyses of cancer related transcriptional networks

CANCER RESEARCH UK (UK)

April 2012 - March 2013

Vacation Scholarship. The role of the Nrf2-keap 1 pathway in regulation of chemoresistance.

WELLCOME TRUST (UK)

July 2008 - August 2008

Regenerative Medicine Platform in Stem Cell Safety Science

MEDICAL RESEARCH COUNCIL

June 2013 - March 2018

Definition of the mechanisms that underlie the decrease in expression of the cytochrome P450s in primary hepatocytes.

BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL

June 2007 - December 2009

Manipulation of the physiological and toxicological phenotype of human hepatocytes by targeting cellular differentiation and de-differentiation

MEDICAL RESEARCH COUNCIL

October 2014 - September 2018

Investigation of Inflammatory Signalling during Drug-induced Hepatotoxicity Background

BRITISH TOXICOLOGY SOCIETY (UK)

October 2007 - September 2010

The chemical and molecular basis of the prevention of drug-induced liver injury by Nrf2.

WELLCOME TRUST (UK)

January 2007 - December 2009

Pharmacogenetic and functional analysis of novel GSTP1 polymorphism.

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

May 2005 - January 2007

Investigation of the role of Nrf2 in man

WELLCOME TRUST (UK)

October 2011 - May 2015

Mechanism and effect of Chinese antioxidant herbs on phase II drug-metabolizing enzymes.

ROYAL SOCIETY (CHARITABLE)

July 2005 - October 2005

Capacity building award in integrative mammalian biology

BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL

January 2007 - October 2015

Biomedical Vacation Scholarships

WELLCOME TRUST (UK)

July 2010 - August 2010

University of Liverpool Institutional Discipline Bridging.

MEDICAL RESEARCH COUNCIL

October 2003 - October 2006

Analysis of inter-individual variation in the inducibility of the antioxidant response by Nrf2: an important element in the defence against cancer.

NORTH WEST CANCER RESEARCH FUND

May 2005 - April 2006

Hepatocyte Phenotype Project: Phase II proposal

STEM CELLS FOR SAFER MEDICINES LTD (UK)

May 2011 - May 2014